The state of estrogen-dependent organs of women with surgical menopause and hormone replacement therapy

The research aims at studying the dynamics and character o f disorders in the target-organs and appraisingthe quality оf life in women with surgical menopause (SM ) on the background o f hormonal replacement therapy (HRT).Application o f Femoston as the preferable preparation was determined by functional state оf estrogen-dependent organs (cardiovascular system, bone tissue, and mamma) and accompanying extragenital diseases.Hormonal replacement therapy effectively reduces early climacterics disorders connected with menopause and promotes prophylaxis o f late complications o f menopause development (cardiovascular disease and osteoporosis). Femoston is the preparation o f choice fo r women with surgical menopause as it exerts minimum influence on the metabolism and doesnt have anabolic or glucocorticoid effects.

Download Full-text

Markers of bone remodeling in patients with surgical menopause undergoing hormone replacement therapy with Divigel

Journal of obstetrics and women s diseases ◽

10.17816/jowd95593 ◽

2021 ◽

Vol 50 (3) ◽

pp. 70-75

Author(s):

S. V. Yureneva ◽

V. P. Smetnik ◽

N. V. Lyubimova ◽

V. M. Abaev

Keyword(s):

Alkaline Phosphatase ◽

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Bone Tissue ◽

Bone Remodeling ◽

Hormone Replacement ◽

Hormonal Replacement Therapy ◽

Mineral Density ◽

Hormonal Replacement ◽

Surgical Menopause

Twenty women with surgical menopause, 40-50 years of age, received hormonal replacement therapy with transdermic preparation Divigel during 24 months. On the background of therapy with Divigel we witnessed normalization of indeces of osteal remodelingconsiderable decrease pyridinoline and deoxypyridinoline, and elevation of alkaline phosphatase. Mineral density of bone tissue in the group of patients with surgical menopause waslowerin comparison with control (p0,01). Divigeltumedto exertprotective influence on the bone tissue inpatients with osteoporosis irrespective о f duration о f surgical menopause by the beginning of therapy.

Download Full-text

Hormone Replacement Therapy and Cardiovascular Disease

PsycEXTRA Dataset ◽

10.1037/e507212006-001 ◽

2004 ◽

Author(s):

Beth R. Malasky

Keyword(s):

Cardiovascular Disease ◽

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Hormone Replacement

Download Full-text

Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease: a protocol for a cohort study from Scotland and Wales

BMC Cancer ◽

10.1186/s12885-021-08065-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Úna McMenamin ◽

Blánaid Hicks ◽

Carmel Hughes ◽

Peter Murchie ◽

Julia Hippisley-Cox ◽

...

Keyword(s):

Cardiovascular Disease ◽

Hormone Replacement Therapy ◽

Venous Thromboembolism ◽

Replacement Therapy ◽

Cancer Diagnosis ◽

Hormone Replacement ◽

All Cause Mortality ◽

Specific Mortality ◽

Cancer Specific Mortality ◽

Risk Of Cancer

Abstract Background Hormone replacement therapy (HRT) is widely used and has proven benefits for women with menopausal symptoms. An increasing number of women with cancer experience menopausal symptoms but the safety of HRT use in women with cancer is unclear. There are particular concerns that HRT could accelerate cancer progression in women with cancer, and also that HRT could increase the risk of cardiovascular disease in such women. Therefore, our primary aim is to determine whether HRT use alters the risk of cancer-specific mortality in women with a range of common cancers. Our secondary objectives are to investigate whether HRT alters the risk of second cancers, cardiovascular disease, venous thromboembolism and all-cause mortality. Methods The study will utilise independent population-based data from Wales using the SAIL databank and Scotland based upon the national Prescribing Information System. The study will include women newly diagnosed with common cancers from 2000 to 2016, identified from cancer registries. Women with breast cancers will be excluded. HRT will be ascertained using electronic prescribing in Wales or dispensing records in Scotland. The primary outcome will be time to cancer-specific mortality from national mortality records. Time-dependent cox regression models will be used to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer specific death in HRT users compared with non-users after cancer diagnosis after adjusting for relevant confounders, stratified by cancer site. Analysis will be repeated investigating the impact of HRT use immediately before cancer diagnosis. Secondary analyses will be conducted on the risk of second cancers, cardiovascular disease, venous thromboembolism and all-cause mortality. Analyses will be conducted within each cohort and pooled across cohorts. Discussion Our study will provide evidence to inform guidance given to women diagnosed with cancer on the safety of HRT use and/or guide modifications to clinical practice.

Download Full-text